Guidelines for Intravenous Glyceryl Trinitrate (GTN) Infusion Beyond 24 Hours

Tolerance Development and Mechanism

Nitrate tolerance is both dose‑ and duration‑dependent, becoming clinically significant after 24 hours of continuous therapy with any GTN formulation (American College of Cardiology; American Heart Association) 1, 2, 3, 4.
Clinically significant tolerance typically develops after 24 hours of continuous GTN infusion, even though the drug remains pharmacologically active, necessitating dose escalation to preserve efficacy (American College of Cardiology) 1, 2.

Patients who require IV GTN beyond 24 hours often need periodic increases in infusion rate to maintain therapeutic effect (American College of Cardiology; American Heart Association) 1, 2, 3, 4.
Recurrence of ischemia during continuous IV GTN can usually be overcome by increasing the infusion dose (American College of Cardiology) 1, 2.
After ischemic symptoms are controlled for several hours, introducing a nitrate‑free interval helps restore vascular sensitivity (American College of Cardiology) 1, 2.
Prolonged GTN infusion (2–4 weeks) at 300–400 µg/min does not raise methemoglobin levels, indicating that methemoglobinemia should not limit dose escalation (American College of Cardiology) 1.

In stabilized patients, IV GTN should be converted within 24 hours to a non‑parenteral nitrate regimen that avoids tolerance (American College of Cardiology) 1, 2.
When patients have been free of ischemic symptoms for 12–24 hours, the IV GTN dose should be tapered and switched to oral or topical nitrates (American College of Cardiology) 1, 2.
Abrupt discontinuation of IV GTN can worsen ischemic ECG changes; a graded dose reduction is therefore recommended (American College of Cardiology) 1, 2.

Nitrate regimens should employ lower doses with intermittent (nitrate‑free) periods to avoid tolerance development (American College of Cardiology; American Heart Association) 1, 2, 3, 4.

Continuing IV GTN is inappropriate in patients who remain free of ischemic signs and symptoms (American College of Cardiology) 1, 2.
Most patients who still require IV GTN for angina relief should be evaluated promptly with coronary angiography and considered for revascularization (American Heart Association) 5.

The evidence supporting nitrate use in acute coronary syndromes is limited; most studies are small, uncontrolled, and lack randomized placebo‑controlled trials demonstrating symptom relief or reduction in cardiac events (American College of Cardiology) 1, 2.
Large trials (ISIS‑4, GISSI‑3) did not show a mortality benefit from routine nitrate therapy, although interpretation is confounded by frequent open‑label nitrate use in control arms (American College of Cardiology) 1, 2.

Tachyphylaxis may occur after approximately 24 hours of continuous IV GTN infusion (American Heart Association) 6.
Systolic blood pressure should not be lowered below 90 mm Hg or more than 30 mm Hg below the patient’s baseline during titration (American College of Cardiology; American Heart Association) 1, 6.
Nitrates should be avoided within 12 hours of avanafil, 24 hours of sildenafil or vardenafil, and 48 hours of tadalafil (American Heart Association) 6.
Continuous monitoring for hypotension, headache, and reflex tachycardia is essential throughout prolonged GTN infusion (American College of Cardiology; American Heart Association) 1, 5.

Transition to oral nitrate should be initiated within 24 hours after the patient has been free of ischemic symptoms for 12–24 hours, to avoid unnecessary prolonged IV therapy. ACC/AHA guideline recommendation. 7, 8, 9, 10
The IV nitroglycerin infusion must be tapered gradually; abrupt discontinuation has been linked to worsening ischemic ECG changes and rebound ischemia. ACC/AHA guideline recommendation. 7, 11

Standard formulation: 5–80 mg administered 2–3 times daily, providing up to 8 hours of anti‑ischemic effect. ACC/AHA guideline recommendation. 7, 8, 12, 13
Sustained‑release formulation: 40 mg given 1–2 times daily, also lasting up to 8 hours. ACC/AHA guideline recommendation. 7, 8, 12, 13

Standard formulation: 20 mg twice daily, delivering a 12–24‑hour duration of effect. ACC/AHA guideline recommendation. 7, 8, 12, 13
Sustained‑release formulation: 60–240 mg once daily, providing continuous coverage with a single dose. ACC/AHA guideline recommendation. 7, 8, 12, 13

A daily nitrate‑free interval of 10–12 hours is essential to maintain efficacy and prevent tolerance development. ACC/AHA guideline recommendation. 7, 8, 9, 10
Clinically significant tolerance typically appears after 24 hours of uninterrupted nitrate therapy, regardless of formulation. ACC/AHA guideline recommendation. 7, 12, 11

Transdermal patches delivering 0.2–0.8 mg/h should be applied for 12 hours each day (not continuously), providing an 8–12‑hour anti‑ischemic window during intermittent therapy. ACC/AHA guideline recommendation. 7, 8, 12, 13
The patch must be removed for a 12‑hour nitrate‑free period daily to avoid tolerance. ACC/AHA guideline recommendation. 7, 9

Nitrates must not be given to patients who have taken phosphodiesterase‑5 inhibitors within the following windows: 12 hours after avanafil, 24 hours after sildenafil or vardenafil, or 48 hours after tadalafil. ACC/AHA guideline recommendation. 14, 15
Nitrates should be avoided in hypotensive patients with systolic blood pressure < 90 mm Hg or a drop > 30 mm Hg from baseline. ACC/AHA guideline recommendation. 7, 12, 14, 15

The ACC/AHA guidelines note that most nitrate studies in unstable angina/NSTEMI are small, uncontrolled, and lack randomized placebo‑controlled trials for symptom relief or reduction of cardiac events; consequently, the evidence base is limited. 7, 8, 11
Large trials (ISIS‑4, GISSI‑3) did not demonstrate a mortality benefit from routine nitrate use, although interpretation is confounded by frequent open‑label nitrate use in control arms. ACC/AHA guideline commentary. 7, 11
The guidelines reference a practical method for converting IV to topical nitroglycerin, but specific conversion formulas are not detailed within the guideline documents. ACC/AHA guideline reference. 7, 12, 9